<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="discussion"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="publisher-id">JCTH</journal-id><journal-title-group><journal-title>Journal of Clinical and Translational Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2225-0719</issn><issn pub-type="epub">2310-8819</issn><publisher><publisher-name>XIA &#x00026; HE Publishing Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9396330</article-id><article-id pub-id-type="publisher-id">JCTH.2022.00278</article-id><article-id pub-id-type="doi">10.14218/JCTH.2022.00278</article-id><article-categories><subj-group subj-group-type="heading"><subject>Hot Topic Commentary</subject></subj-group></article-categories><title-group><article-title>SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?</article-title><alt-title alt-title-type="running-head-verso">Patoulias D. <italic>et al</italic>: SGLT-2i &#x00026; GLP-1RA combination for NAFLD</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Patoulias</surname><given-names>Dimitrios</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="COR1" ref-type="corresp">*</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6899-684X</contrib-id></contrib><contrib contrib-type="author"><name><surname>Michailidis</surname><given-names>Theodoros</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><aff id="aff1"><label>1</label>Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital &#x0201c;Hippokration,&#x0201d; Thessaloniki, Greece</aff><aff id="aff2"><label>2</label>Second Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital &#x0201c;Hippokration,&#x0201d; Thessaloniki, Greece</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label><bold>Correspondence to:</bold> Dimitrios Patoulias, Second Propedeutic Department of Internal Medicine, General Hospital &#x0201c;Hippokration,&#x0201d; Konstantinoupoleos 49, 54642, Thessaloniki, Greece. ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-6899-684X" ext-link-type="uri">https://orcid.org/0000-0002-6899-684X</ext-link>. Tel: +30-6946900777, Fax: +30-2310225083, E-mail: <email>dipatoulias@gmail.com</email></corresp><fn fn-type="financial-disclosure"><p>None to declare.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflict of interests related to this publication.</p></fn><fn fn-type="con"><p>DP and TM wrote the draft, DP critically revised the manuscript before submission.</p></fn></author-notes><pub-date pub-type="ppub"><day>28</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>13</day><month>7</month><year>2022</year></pub-date><volume>10</volume><issue>4</issue><fpage>574</fpage><lpage>576</lpage><history><date date-type="received"><day>5</day><month>6</month><year>2022</year></date><date date-type="rev-recd"><day>16</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions></article-meta></front><body><p>Nonalcoholic fatty liver disease (NAFLD) is a growing epidemic, representing the most common chronic liver disease worldwide.<xref rid="JCTH-D-22-00278-b1" ref-type="bibr">1</xref> NAFLD is highly associated with type 2 diabetes mellitus (T2DM) and obesity, conditions that increase morbidity and mortality.<xref rid="JCTH-D-22-00278-b2" ref-type="bibr">2</xref> A background of T2DM has also been shown to be predictive of cirrhosis and hepatocellular carcinoma occurrence in patients with T2DM, and cirrhotic patients with diabetes seem to have a higher risk of hepatic decompensation with manifestations of hepatic encephalopathy.<xref rid="JCTH-D-22-00278-b3" ref-type="bibr">3</xref> In addition, it should not be underestimated the significantly increased risk for cardiovascular disease (CVD) and chronic kidney disease (CKD) in subjects with NAFLD, regardless of T2DM presence.<xref rid="JCTH-D-22-00278-b4" ref-type="bibr">4</xref>,<xref rid="JCTH-D-22-00278-b5" ref-type="bibr">5</xref></p><p>Newer antidiabetic drugs, like sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have attracted scientific interest in the last decade, because of their multiple pleiotropic effects, with emphasis on cardio- and reno-protection with both drug classes.<xref rid="JCTH-D-22-00278-b6" ref-type="bibr">6</xref> Their potential role in the treatment of NAFLD has been widely discussed recently.<xref rid="JCTH-D-22-00278-b7" ref-type="bibr">7</xref></p><p>A previous meta-analysis demonstrated that both drug classes provided a significant improvement in liver enzymes and steatosis in patients with NAFLD.<xref rid="JCTH-D-22-00278-b8" ref-type="bibr">8</xref> Two recent meta-analyses confirmed the beneficial effects of these drug classes on liver enzymes and liver fibrosis, along with significant improvements in the overall metabolic profile and glycemic control.<xref rid="JCTH-D-22-00278-b9" ref-type="bibr">9</xref>,<xref rid="JCTH-D-22-00278-b10" ref-type="bibr">10</xref> What is more, a recently published retrospective study documented that 5-year treatment with SGLT-2 inhibitors in patients with T2DM and NAFLD resulted in a significant improvement in liver steatosis and fibrosis, and that addition of a GLP-1RA was safe.<xref rid="JCTH-D-22-00278-b11" ref-type="bibr">11</xref> It has also been speculated that their diuretic effects might be of great value for cirrhotic patients with refractory ascites.<xref rid="JCTH-D-22-00278-b12" ref-type="bibr">12</xref> Some anecdotal data retrieved from small case series support this hypothesis.<xref rid="JCTH-D-22-00278-b13" ref-type="bibr">13</xref></p><p>Regarding GLP-1RAs, a previous population-based retrospective cohort study found that treatment with this antidiabetic drug class resulted in a significant decrease in the risk of individual decompensation events, including ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, esophageal variceal hemorrhage, and hepatic encephalopathy.<xref rid="JCTH-D-22-00278-b14" ref-type="bibr">14</xref> However, when SGLT-2 inhibitors and GLP-1RAs were directly compared, no significant difference in decompensation rates was observed.<xref rid="JCTH-D-22-00278-b14" ref-type="bibr">14</xref> Combining SGLT-2 inhibitors and GLP-1RA has been shown to be safe and highly efficacious in patients with T2DM, providing a greater reduction in glycated hemoglobin levels, body weight, and systolic blood pressure, compared with each drug class alone.<xref rid="JCTH-D-22-00278-b15" ref-type="bibr">15</xref> In addition, the cardiovascular benefit obtained by combining a SGLT-2 inhibitor and GLP-1RA seems to be greater than that obtained with a SGLT-2 inhibitor or GLP-1RA alone.<xref rid="JCTH-D-22-00278-b16" ref-type="bibr">16</xref></p><p>Unfortunately, except for the observations made by Akuta and colleagues<xref rid="JCTH-D-22-00278-b11" ref-type="bibr">11</xref> in a small cohort of patients with NAFLD,<xref rid="JCTH-D-22-00278-b11" ref-type="bibr">11</xref> there is no evidence of a synergistic effect of a SGLT-2 inhibitor plus GLP-1RA on liver steatosis and/or fibrosis in patients with NAFLD. The greater reductions of glycated hemoglobin level and body weight shown in previous randomized controlled trials and meta-analyses, should be considered a major step in achieving increased benefits with treatment of liver steatosis by combining a SGLT-2 inhibitor and GLP-1RA.<xref rid="JCTH-D-22-00278-b15" ref-type="bibr">15</xref> In addition, greater reductions in subcutaneous fat and the visceral fat mass, should be expected with such a combination, along with a greater reduction in intrahepatic fat content, although that has to be confirmed in future trials.<xref rid="JCTH-D-22-00278-b17" ref-type="bibr">17</xref>,<xref rid="JCTH-D-22-00278-b18" ref-type="bibr">18</xref> Remarkably, only an observational study in a total of 24 patients with NAFLD and T2DM showed that addition of a SGLT-2 inhibitor to an incretin-based regimen with GLP-1RA or a DPP-4 inhibitor resulted in a significant decrease in alanine aminotransferase levels that led to normalization and in a significant improvement in the FIB-4 index.<xref rid="JCTH-D-22-00278-b19" ref-type="bibr">19</xref></p><p>Of course, it has to be admitted that the safety and efficacy of a great number of drug classes and investigational agents for the treatment of NAFLD with or without comorbidities testing are currently under investigation in clinical trials.<xref rid="JCTH-D-22-00278-b20" ref-type="bibr">20</xref> Peroxisome proliferator-activated receptor agonists, pyruvate carrier (MPC) inhibitors, farnesoid X receptor agonists, liver X receptor alpha inhibitors, fibroblast growth factor analogs/activators, dual GLP-1 and glucose-dependent insulinotropic peptide receptor analogs or agonists, thyroid hormone receptor (THR-&#x003b2;)-selective agonists, antioxidants, fibrosis-targeted treatment options, and their combinations, are being assessed for their potential incorporation into the armamentarium of NAFLD treatments.<xref rid="JCTH-D-22-00278-b20" ref-type="bibr">20</xref> Of note, some are also being tested in combination with either SGLT-2 inhibitors or GLP-1RAs.<xref rid="JCTH-D-22-00278-b20" ref-type="bibr">20</xref></p><p>Therefore, it appears that such a combination would be of great value for patients with NAFLD and comorbidities, such as obesity, CVD, or even CKD (a simplified treatment approach is shown in <xref rid="JCTH-D-22-00278-f1" ref-type="fig">Fig. 1</xref>). However, no studies have yet assessed the impact of such a combination on histological outcomes in patients with NAFLD and T2DM to confirm whether an SGLT-2 inhibitor/GLP-1RA combination might have beneficial synergistic effects on liver steatosis and fibrosis. Well-designed, prospective studies are required to answer this sound, scientific question. In addition, cost-effectiveness analyses are needed.</p><fig position="float" id="JCTH-D-22-00278-f1"><label>Fig. 1</label><caption><title>A simplified treatment approach for patients with NAFLD and type 2 diabetes mellitus.</title><p>NAFLD, nonalcoholic fatty liver disease.</p></caption><graphic xlink:href="JCTH-10-574-g001" position="float"/></fig></body><back><ref-list><title>References</title><ref id="JCTH-D-22-00278-b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappachan</surname><given-names>JM</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name><name><surname>Krishnan</surname><given-names>B</given-names></name><name><surname>Ravindran</surname><given-names>NC</given-names></name></person-group><article-title>Non-alcoholic Fatty Liver Disease: A Clinical Update</article-title><source>J Clin Transl Hepatol</source><year>2017</year><volume>5</volume><issue>4</issue><fpage>384</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2017.00013</pub-id><pub-id pub-id-type="pmid">29226105</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Priyadarshi</surname><given-names>RN</given-names></name><name><surname>Anand</surname><given-names>U</given-names></name></person-group><article-title>Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations</article-title><source>J Clin Transl Hepatol</source><year>2020</year><volume>8</volume><issue>1</issue><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2019.00051</pub-id><pub-id pub-id-type="pmid">32274348</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raff</surname><given-names>EJ</given-names></name><name><surname>Kakati</surname><given-names>D</given-names></name><name><surname>Bloomer</surname><given-names>JR</given-names></name><name><surname>Shoreibah</surname><given-names>M</given-names></name><name><surname>Rasheed</surname><given-names>K</given-names></name><name><surname>Singal</surname><given-names>AK</given-names></name></person-group><article-title>Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases</article-title><source>J Clin Transl Hepatol</source><year>2015</year><volume>3</volume><issue>1</issue><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2015.00001</pub-id><pub-id pub-id-type="pmid">26356325</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Csermely</surname><given-names>A</given-names></name><name><surname>Petracca</surname><given-names>G</given-names></name><name><surname>Beatrice</surname><given-names>G</given-names></name><name><surname>Corey</surname><given-names>KE</given-names></name><name><surname>Simon</surname><given-names>TG</given-names></name><etal/></person-group><article-title>Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis</article-title><source>Lancet Gastroenterol Hepatol</source><year>2021</year><volume>6</volume><issue>11</issue><fpage>903</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(21)00308-3</pub-id><pub-id pub-id-type="pmid">34555346</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Zaza</surname><given-names>G</given-names></name><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Lonardo</surname><given-names>A</given-names></name><name><surname>Zoppini</surname><given-names>G</given-names></name><name><surname>Bonora</surname><given-names>E</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis</article-title><source>Metabolism</source><year>2018</year><volume>79</volume><fpage>64</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2017.11.003</pub-id><pub-id pub-id-type="pmid">29137912</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Heerspink</surname><given-names>HJL</given-names></name><name><surname>Cuthbertson</surname><given-names>DJ</given-names></name><name><surname>Wilding</surname><given-names>JPH</given-names></name></person-group><article-title>SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications</article-title><source>Lancet</source><year>2021</year><volume>398</volume><issue>10296</issue><fpage>262</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00536-5</pub-id><pub-id pub-id-type="pmid">34216571</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>HS</given-names></name><name><surname>Sakaan</surname><given-names>SA</given-names></name><name><surname>March</surname><given-names>KL</given-names></name><name><surname>Siddique</surname><given-names>O</given-names></name><name><surname>Cholankeril</surname><given-names>R</given-names></name><name><surname>Cummings</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies</article-title><source>J Clin Transl Hepatol</source><year>2018</year><volume>6</volume><issue>2</issue><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2017.00050</pub-id><pub-id pub-id-type="pmid">29951362</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>J</given-names></name><name><surname>Memon</surname><given-names>RS</given-names></name><name><surname>Shahid</surname><given-names>I</given-names></name><name><surname>Rizwan</surname><given-names>T</given-names></name><name><surname>Zaman</surname><given-names>M</given-names></name><name><surname>Menezes</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map</article-title><source>Dig Liver Dis</source><year>2021</year><volume>53</volume><issue>1</issue><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2020.08.021</pub-id><pub-id pub-id-type="pmid">32912770</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Lian</surname><given-names>P</given-names></name><name><surname>Ran</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis</article-title><source>Acta Diabetol</source><year>2022</year><volume>59</volume><issue>4</issue><fpage>519</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1007/s00592-021-01830-7</pub-id><pub-id pub-id-type="pmid">34988690</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Chin</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Syn</surname><given-names>N</given-names></name><name><surname>Goh</surname><given-names>XL</given-names></name><etal/></person-group><article-title>Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials</article-title><source>Endocr Pract</source><year>2022</year><volume>28</volume><issue>2</issue><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.eprac.2021.09.013</pub-id><pub-id pub-id-type="pmid">34606980</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akuta</surname><given-names>N</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Fujiyama</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Muraishi</surname><given-names>N</given-names></name><name><surname>Sezaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study</article-title><source>Hepatol Commun</source><year>2022</year><pub-id pub-id-type="doi">10.1002/hep4.2005</pub-id><pub-id pub-id-type="pmid">35581956</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>DD</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>B</given-names></name></person-group><article-title>SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites</article-title><source>J Clin Transl Hepatol</source><year>2021</year><volume>9</volume><issue>6</issue><fpage>795</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2021.00418</pub-id><pub-id pub-id-type="pmid">34966642</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalvo-Gordon</surname><given-names>I</given-names></name><name><surname>Chi-Cervera</surname><given-names>LA</given-names></name><name><surname>Garc&#x000ed;a-Tsao</surname><given-names>G</given-names></name></person-group><article-title>Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><issue>5</issue><fpage>1880</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1002/hep.31270</pub-id><pub-id pub-id-type="pmid">32294260</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>TG</given-names></name><name><surname>Patorno</surname><given-names>E</given-names></name><name><surname>Schneeweiss</surname><given-names>S</given-names></name></person-group><article-title>Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes</article-title><source>Clin Gastroenterol Hepatol</source><year>2022</year><volume>20</volume><issue>6</issue><fpage>1382</fpage><lpage>1393.e19</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2021.07.010</pub-id><pub-id pub-id-type="pmid">34256144</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantsiou</surname><given-names>C</given-names></name><name><surname>Karagiannis</surname><given-names>T</given-names></name><name><surname>Kakotrichi</surname><given-names>P</given-names></name><name><surname>Malandris</surname><given-names>K</given-names></name><name><surname>Avgerinos</surname><given-names>I</given-names></name><name><surname>Liakos</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis</article-title><source>Diabetes Obes Metab</source><year>2020</year><volume>22</volume><issue>10</issue><fpage>1857</fpage><lpage>1868</lpage><pub-id pub-id-type="doi">10.1111/dom.14108</pub-id><pub-id pub-id-type="pmid">32476254</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patoulias</surname><given-names>D</given-names></name><name><surname>Papadopoulos</surname><given-names>C</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Doumas</surname><given-names>M</given-names></name></person-group><article-title>Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?</article-title><source>Eur J Intern Med</source><year>2022</year><volume>98</volume><fpage>125</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">34969593</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Mu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>769069</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.769069</pub-id><pub-id pub-id-type="pmid">34956080</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>635556</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.635556</pub-id><pub-id pub-id-type="pmid">34220701</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohki</surname><given-names>T</given-names></name><name><surname>Isogawa</surname><given-names>A</given-names></name><name><surname>Toda</surname><given-names>N</given-names></name><name><surname>Tagawa</surname><given-names>K</given-names></name></person-group><article-title>Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors</article-title><source>Clin Drug Investig</source><year>2016</year><volume>36</volume><issue>4</issue><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1007/s40261-016-0383-1</pub-id><pub-id pub-id-type="pmid">26914659</pub-id></element-citation></ref><ref id="JCTH-D-22-00278-b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negi</surname><given-names>CK</given-names></name><name><surname>Babica</surname><given-names>P</given-names></name><name><surname>Bajard</surname><given-names>L</given-names></name><name><surname>Bienertova-Vasku</surname><given-names>J</given-names></name><name><surname>Tarantino</surname><given-names>G</given-names></name></person-group><article-title>Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease</article-title><source>Metabolism</source><year>2022</year><volume>126</volume><fpage>154925</fpage><pub-id pub-id-type="doi">10.1016/j.metabol.2021.154925</pub-id><pub-id pub-id-type="pmid">34740573</pub-id></element-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>CKD</term><def><p>chronic kidney disease</p></def></def-item><def-item><term>CVD</term><def><p>cardiovascular disease</p></def></def-item><def-item><term>GLP-1RA</term><def><p>glucagon-like peptide-1 receptor agonists</p></def></def-item><def-item><term>NAFLD</term><def><p>nonalcoholic fatty liver disease</p></def></def-item><def-item><term>SGLT-2</term><def><p>sodium-glucose co-transporter-2</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item></def-list></glossary></back></article>
